Advertisement

Drugs

, Volume 2, Issue 2, pp 78–137 | Cite as

Diazoxide: A Review of its Pharmacological Properties and Therapeutic Use in Hypertensive Crises

Evaluations on New Drugs

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

11. References

  1. Andreasen, F.V.V.: Protein binding and initial distribution of diazoxide. Federation Proceedings 28: 614 (1969).Google Scholar
  2. Appleyard, W.J.: Pluriglandular syndrome with hyper-insulinism. Cardiomegaly as a possible complication of diazoxide therapy. Proceedings of the Royal Society of Medicine 61: 1257–1258(1968).PubMedGoogle Scholar
  3. Baer, L.; Goodwin, F.J., and Laragh, J.H.: Diazoxide-induced renin release in man: Dissociation from plasma and extracellular fluid volume changes. Journal of Clinical Endocrinology 29: 1107–1109 (1969).CrossRefGoogle Scholar
  4. Baker, L. and Miller, M.E.: Depression of immuno-globulin-G (IgG) levels associated with diazoxide therapy. Metabolism 16: 964–966 (1967).CrossRefGoogle Scholar
  5. Balsam, MarionJ.: Personal communication (1971).Google Scholar
  6. Balsam, Marion J.; Baker, L., and Kaye, R.: Hyperosmolar nonketotic coma associated with diazoxide therapy for hypoglycemia. Journal of Pediatrics 78: 523–525(1971).PubMedCrossRefGoogle Scholar
  7. Bartorelli, C.; Gargano, N.; Leonetti, G., and Zanchetti, A.: Hypotensive and renal effects of diazoxide, a sodium-retaining benzothiadiazine compound. Circulation 27: 895–903 (1963).PubMedCrossRefGoogle Scholar
  8. Beamer, Virginia L. and McDonald, R.H.: Failure of repeated diazoxide injections to modify the course of severe hypertension. American Heart Journal 79: 742–751(1970).PubMedCrossRefGoogle Scholar
  9. Bhatia, S. and Frohlich, E.D.: A hemodynamic comparison of agents useful in hypertensive emergencies. Clinical Pharmacology and Therapeutics 12: 287 (1971).Google Scholar
  10. Black, J.: Diazoxide and the treatment of hypoglycaemia: An historical review. Annals of the New York Academy of Sciences 150: 194(1968).PubMedCrossRefGoogle Scholar
  11. Blackard, W.G. and Aprill, C.N.: Mechanism of action of diazoxide. Journal of Laboratory and Clinical Medicine 69: 960–967 (1967).PubMedGoogle Scholar
  12. Boulos, B.M.; Davis, L.E.; Almond, C.H., and Jackson, R.L.: Placental transfer of diazoxide and its hazardous effect on the newborn. Journal of Clinical Pharmacology and New Drugs 11: 206 (1971).PubMedGoogle Scholar
  13. Boyarsky, S. and Labay, Peregrina: The effect of diazoxide, an antidiuretic thiazide on ureteral peristalsis. Clinical Research 16: 474(1968).Google Scholar
  14. Calesnick, B.; Katchen, B., and Black, J.: Importance of dissolution rates in producing effective diazoxide blood levels in man. Journal of Pharmaceutical Sciences 54: 1227–1280(1965).CrossRefGoogle Scholar
  15. Combs, J.T.; Grunt, J.A., and Brande, I.K.: Hematologic reactions to diazoxide. Pediatrics 40: 90–92 (1967).PubMedGoogle Scholar
  16. Conway, J.; Keitzer, F., and Miller, J.D.: Hemodynamic Effects of a sodium-retaining thiazide derivative: Preliminary observations. Journal of Laboratory and Clinical Medicine 58: 809(1961).Google Scholar
  17. Crout, J.R.: Personal communication (1971).Google Scholar
  18. Crout, J.R.; Andreasen, F. V. V.; Parks, R.I., and Heimbach, D.C.: Intravenous diazoxide in hypertension. Clinical Research 18: 337 (1970).Google Scholar
  19. Davidov, M.; Kakaviatos, N., and Finnerty, F.A.,Jr.: Antihypertensive properties of furosemide. Circulation 36: 125(1967).PubMedCrossRefGoogle Scholar
  20. Dollery, C.T.; Pentecost, B.L., and Samaan, N.A.: Drug-induced diabetes. Lancet 2: 735 (1962).PubMedCrossRefGoogle Scholar
  21. Dunea, G. and Gantt, C.L.: Diazoxide in hypertensive crisis. Lancet 2: 638–639(1966).CrossRefGoogle Scholar
  22. Ehrlich, E.N.: Cortisol responses to diazoxide in man and their possible relationship to effective blood volume. Metabolism 19: 469–470 (1970).PubMedCrossRefGoogle Scholar
  23. Fajans, S.S.; Floyd, J.C.; Knopf, R.F.; Rull, J; Guntsche, EM., and Conn, J. W.: Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. Journal of Clinical Investigation 45: 481–491(1966).PubMedCrossRefGoogle Scholar
  24. Finnerty, F.A.: Newer antihypertensive drugs. Medical Clinics of North America 48: 329–333 (1964).PubMedGoogle Scholar
  25. Finnerty, F.A.: Hypertensive encephalopathy. American Heart Journal 75: 559–563 (1968).PubMedCrossRefGoogle Scholar
  26. Finnerty, F.A.: Advantages and disadvantages of furosemide in the edematous states of pregnancy. American Journal of Obstetrics and Gynecology 105: 1022–1027(1969).PubMedGoogle Scholar
  27. Finnerty, F.A.: Treatment of acute hypertension in pregnancy. Obstetrics Gynecology Digest 12: 30–37 (1970).Google Scholar
  28. Finnerty, F.A.: Relationship of extracellular fluid volume to the development of drug resistance in the hypertensive patient. American Heart Journal 81: 563–565 (1971a).PubMedCrossRefGoogle Scholar
  29. Finnerty, F.A.: Failure of repeated diazoxide injections to modify the course of severe hypertension. American Heart Journal 81: 724 (1971 b).PubMedCrossRefGoogle Scholar
  30. Finnerty, F.A.; Davidov, M., and Kakaviatos, N.: The long-term effect of rapid repeated reductions of arterial pressure with diazoxide. American Journal of Cardiology 19: 337–384(1967).CrossRefGoogle Scholar
  31. Finnerty, F.A. and Kakaviatos, N.: Ideal treatment for hypertensive encephalopathy. Circulation 26: 715 (1962).Google Scholar
  32. Finnerty, F.A.; Kakaviatos, N., and Davidov, M.: The long-term effect of repeated acute reductions of arterial pressure with diazoxide in patients with severe hypertension. Annals of the New York Academy of Science 150:461–463 (1968).CrossRefGoogle Scholar
  33. Finnerty, F.A.; Kakaviatos, N.; Chupkovich, V.; Tuckman, J., and Marshall, J.: Value of diazoxide administered intravenously in acute hypertension. Circulation 28: 719–720(1963b).CrossRefGoogle Scholar
  34. Finnerty, F.A.; Kakaviatos, N.; Tuckman, J., and Magill, J.: Clinical evaluation of diazoxide. A new treatment for acute hypertension. Circulation 28: 203–208 (1963a).PubMedCrossRefGoogle Scholar
  35. Greene, J.A.: Effects of diazoxide on renal function in the dog. Proceedings of the Society for Experimental Biology and Medicine 125: 375 379(1967).PubMedGoogle Scholar
  36. Gutman, Y.; Bergmann, F., and Banzakein, F.: Effect of diazoxide and chlorothiazide on absorption from the small intestine in vivo. Life Sciences 7: 189–195 (1968).PubMedCrossRefGoogle Scholar
  37. Hamby, W.M.; Janokwski, G.J.; Pouget, J.M.; Dunea, G., and Gantt, C.L.: Intravenous use of diazoxide in the treatment of severe hypertension. Circulation 37: 169–174(1968).CrossRefGoogle Scholar
  38. Hutcheon, D.E. and Barthalmus, Katherine, S.: Antihypertensive action of diazoxide. British Medical Journal 2: 159–161(1962).PubMedCrossRefGoogle Scholar
  39. Johnson, B.: Renal actions of diazoxide in hypertensives. Clinical Research 16: 386(1968).Google Scholar
  40. Just, H. and Stein, J.: Studies on the effect of diazoxide, a new hypotensive drug, on the systemic and pulmonary circulation in hypertensive subjects. Zeitschrift für Kreislaufforschung 55: 925–936 (1969).Google Scholar
  41. Kakaviatos, N. and Finnerty, F.A.: Preliminary observations on the value of diazoxide administered intravenously in man. Angiology 13: 541–544 (1962).Google Scholar
  42. Kakaviatos, N.; Davidov, M., and Finnerty, F.A.: The ability to reset the barostat of arterial blood pressure in man. Clinical Research 14: 251 (1966).Google Scholar
  43. Kakaviatos, N.; Davidov, M., and Finnerty, F.A.: Acute reduction of arterial pressure associated with an increase in effective renal plasma flow. Clinical Research 16: 62(1968).Google Scholar
  44. Kakaviatos, N.; Davidov, M.; Garvilovic, Lillian, and Finnerty, F.A.: Diazoxide and frusemide in hypertension. Lancet 2: 725(1967).CrossRefGoogle Scholar
  45. Kakaviatos, N.; Tuckman, J., and Finnerty, F.A.: An antihypertensive agent which reduces peripheral resistance. Clinical Research 10: 174(1962).Google Scholar
  46. Kapitola, J.; Kuchel, O.; Schreiberova, O., and Jahoda, I.: Decreased thyroid radio-iodine uptake after diazoxide in rats. Experientia 24: 50–51 (1968a).PubMedCrossRefGoogle Scholar
  47. Kapitola, J.; Kuchel, O.; Schreiberova, O., and Jahoda, I.: Further contribution to the effect of diazoxide on the thyroid gland in rats. Experientia 24: 810–811 (1968b).PubMedCrossRefGoogle Scholar
  48. Kincaid-Smith, Priscilla: Personal communication (1971).Google Scholar
  49. Kuchel, O.; Fishman, L.M.; Liddie, G.W., and Michelakis, A.: Effect of diazoxide on plasma renin activity in hypertensive patients. Annals of Internal Medicine 67: 791–799(1967).PubMedGoogle Scholar
  50. Landesman, R. and Wilson, Kathleen, H.: The relaxant effect of diazoxide on isolated gravid and nongravid human myometrium. American Journal of Obstetrics and Gynecology 101: 120–125(1968).PubMedGoogle Scholar
  51. Landesman, R.; Coutinho, E.M.; Wilson, Kathleen, H., and Lopes, A.C.V.: The relaxant effect of diazoxide on nongravid human myometrium in vivo. American Journal of Obstetrics and Gynecology 102: 1080–1084(1968).PubMedGoogle Scholar
  52. Landesman, R.; Souza, J.A. de; Coutinho, EM.; Wilson, Kathleen H., and Sousa, M.B. de: The inhibitory effect of diazoxide in normal term labor. American Journal of Obstetrics and Gynecology 103: 430–433(1969).PubMedGoogle Scholar
  53. Leifer, J.R.; Meisner, E., and Lipowitz, M.: A clinical evaluation of diazoxide in the treatment of hypertension. Journal of the Newark Beth Israel Hospital 19: 127–132(1968).Google Scholar
  54. Leonetti, G.; Grazi, S.; Ligresti, A.; Romano, S., and Zanchetti, A.: Autonomic and renal effects of intravenous diazoxide. A study of the mechanisms of its hypotensive action inman. Pharmacologia Clinica 2: 206–215(1970).CrossRefGoogle Scholar
  55. Lockwood, C.H.; Nicholls, Doris M.; Troop, Virginia L., and Lewis, J.A.: Diazoxide therapy in hypertension. American Journal of the Medical Sciences 246: 312–318(1963).PubMedCrossRefGoogle Scholar
  56. Loubatières, A.; Mariant, M.M, and Alric, R.: The action of diazoxide on insulin secretion, medullo-adrenal secretion, and the liberation of catecholamines. Annals of the New York Academy of Sciences 750: 226(1968).CrossRefGoogle Scholar
  57. McNeill, J.H.; Barnes, R.V.; Davis, R.S., and Hook, J.B.: The effect of vasodilator drugs on the noradrenaline constrictor response in the isolated mesenteric artery. Canadian Journal of Physiology and Pharmacology 47: 663–669 (1969).PubMedCrossRefGoogle Scholar
  58. Malaisse, W. and Malaisse-Lagae, Francine: Effects of glycodiazin and glybenclamide upon insulin secretion in vitro. European Journal of Pharmacology 9: 93–98 (1970).PubMedCrossRefGoogle Scholar
  59. Meurer, K.A.; Ganten, D., and Kaufmann, W.: Testverfahren zur Prüfung der Stimulierbarkeit der Plasma-Renin-Aktivität. Deutsche Medizinische Wochenschrift 95: 1404(1970).PubMedCrossRefGoogle Scholar
  60. Miller, W.E.; Gifford, R.W.; Humphrey, D.C., and Vidt, D.G.: Management of severe hypertension with intravenous injections of diazoxide. American Journal of Cardiology 24: 870–875 (1969).PubMedCrossRefGoogle Scholar
  61. Milton, R.M. and Taylor, R.M.: Further studies on the renal pharmacology of diazoxide. Federation Proceedings 21: 432(1962).Google Scholar
  62. Moore, P.F.: The effects of diazoxide and benzothiadiazine diuretics upon phosphodiesterase. Annals of the New York Academy of Sciences 150: 256–260 (1968).PubMedCrossRefGoogle Scholar
  63. Mroczek, W.J.; Davidov, M.; Gavrilovich, Lilian, and Finnerty, F.A.: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904 (1969b).CrossRefGoogle Scholar
  64. Mroczek, W.; Gavrilovich, Lillian, Davidov, M., and Finnerty, F.A.: The safe reduction of arterial pressure in hypertensive uremic patients. American Journal of Cardiology 23: 129 (1969a).CrossRefGoogle Scholar
  65. Nayler, Winifred G.; McInnes, L; Swann, J.B.; Race, D.; Carson, Valerie, and Lowe, T.E: Some effects of the hypotensive drug diazoxide on the cardiovascular system. American Heart Journal 75: 223–232 (1968).PubMedCrossRefGoogle Scholar
  66. Nellen, M.: Diazoxide in the treatment of hypertension. South African Medical Journal 44: 106–108 (1970).PubMedGoogle Scholar
  67. Okun, R.; Russell, R.P., and Wilson, W.R.: Use of diazoxide with trichlormethiazide for hypertension. Archives of Internal Medicine 112: 882–888(1963).PubMedGoogle Scholar
  68. Okun, R.; Wilson, W.R., and Gelfand, M.D.: The hyperglycemic effect of hypotensive drugs. Journal of Chronic Diseases 17: 31–39(1964).PubMedCrossRefGoogle Scholar
  69. Parish, A.E.; Kramer, N.C.; Bowman, W.K.; Miller, M.S., and Watt, Mary, F.: Hypotensive agents in renal biopsy. Journal of the American Medical Association 189: 380–381(1964).CrossRefGoogle Scholar
  70. Pereda, S.A.; Eckstein, J.W., and Abboud, F.M.: Effect of diazoxide on vascular responses to norepinephrine in the calf of normal subjects. Proceedings of the Society for Experimental Biology and Medicine 772: 709–712(1963).Google Scholar
  71. Powell, W.J., Jr.; Green, R.M.; Whiting, R.B., and Sanders, C.A.: Action of diazoxide on skeletel muscle vascular resistance. Circulation Research 28: 167–178 (1971).PubMedCrossRefGoogle Scholar
  72. Pruitt, A. W.; Dayton, P.G., and Patterson, J.H.: Studies of diazoxideinchildren.Pharmacologist 13: 196(1971).Google Scholar
  73. Ramaswamy, D. and Richardson, D.W.: Mechanism of circulatory effects of intravenous diazoxide. Circulation 37 and 38 (Suppl. 6): 160 (1968).Google Scholar
  74. Rennick, Barbara; Pryor, Marilyn, and Yoss, Norma: Inhibition of the renal tubular transport of epinephrine by the benzothiadiazine compounds. Journal of Pharmacology and Experimental Therapeutics 143: 42–46(1964).PubMedGoogle Scholar
  75. Robb, G.H.: A fatal reaction to diazoxide. Postgraduate Medical Journal 45: 43–45 (1969).PubMedCrossRefGoogle Scholar
  76. Rowe, G.G.; Leicht, T.R.; Boake, W.C.; Kyle, J.C, and Crumpton, C.W.: The systemic and coronary hemodynamic effects of diazoxide. American Heart Journal 66: 636–643(1963).PubMedCrossRefGoogle Scholar
  77. Rubin, A.A.: Hemodynamic aspects of certain antihypertensive agents. Angiology 14: 74–78 (1963).PubMedCrossRefGoogle Scholar
  78. Rubin, A.A.; Roth, F.E.; Taylor, R.M., and Rosenkilde, H.: Pharmacology of diazoxide, an antihypertensive, non-diuretic benzothiadiazine. Journal of Pharmacology and Experimental Therapeutics 136: 344–352 (1962).PubMedGoogle Scholar
  79. Rubin, A.A.; Roth, F.E., and Winbury, M.M.: A non-diuretic benzothiadiazine with anti-hypertensive properties. Nature 792: 176–177 (1961).CrossRefGoogle Scholar
  80. Rubin, A.A.; Roth, F.E; Winbury, M.M.; Topliss, J.G.; Sherlock, Margaret H; Sperber, N., and Black, J.: New class of anti-hypertensive agents. Science 133: 2067(1961).PubMedCrossRefGoogle Scholar
  81. Rubin, A.A.; Taylor, R.M., and Roth, F.E.: A brief review of the development of diazoxide as an antihypertensive agent. Annals of the New York Academy of Sciences 150: 457–460(1968).PubMedCrossRefGoogle Scholar
  82. Rubin, A.A.; Zitowitz, L., and Hausier, Lorraine: Acute circulatory effects of diazoxide and sodium nitrite. Journal of Pharmacology and Experimental Therapeutics 140: 46–51 (1963).PubMedGoogle Scholar
  83. Saker, B.M.; Mathew, T.H.; Eremin, Jennifer, and Kincaid-Smith, Priscilla: Diazoxide in the treatment of the acute hypertensive emergency. Medical Journal of Australia 7: 592–593(1968).Google Scholar
  84. Sanbar, S.S.; Mitchell, S.A.; Lockey, R.F.; Vicek, E.A., and Green, J.A.: Metabolic effects of hypotension induced by hemorrhage and by hypotensive drugs. Clinical Research75: 410(1967).Google Scholar
  85. Schafer, G; Wegener, C.; Portenhauser, R.,and Bojanovski, D.: Diazoxide, an inhibitor of succinate oxidation. Biochemical Pharmacology 18: 2678–2681 (1969).PubMedCrossRefGoogle Scholar
  86. Scott, J.C. and Cowley, A.W.: The effect of diazoxide on coronary blood flow. American Journal of Cardiology 24: 865–869 (1969).PubMedCrossRefGoogle Scholar
  87. Sellers, E.M.: Personal communication (1971).Google Scholar
  88. Sellers, E.M. and Itskovitz, H.D.: Acute hypotensive use of diazoxide. Circulation 28: 801 (1963).Google Scholar
  89. Sellers, E.M. and Koch-Weser, J.: Protein binding and vascular activity of diazoxide. New England Journal of Medicine 257: 1141–1145(1969).CrossRefGoogle Scholar
  90. Sellers, E.M. and Koch-Weser, J.: Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic and nalidixic acids. Clinical Pharmacology and Therapeutics 77: 524–529 (1970).Google Scholar
  91. Seltzer, H.S. and Allen, E. W.: Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man. Diabetes 18: 19 (1969).PubMedGoogle Scholar
  92. Senft, G.: Biochemical aspects of the hyperglycaemic action of diazoxide. Annals of the New York Academy of Sciences 750: 242 (1968).CrossRefGoogle Scholar
  93. Spitzer, J.J. and Scott, J.C: Effects of diazoxide on myocardial free fatty acid metabolism and hemodynamics in the dog. Archives internationales de pharmaco-dynamie et de thérapie 184: 405–414 (1970).Google Scholar
  94. Stanton, H.C. and White, J.B.: Hypotensive actions of drugs on unanesthetised normotensive and ‘Metacorticoid’ hypertensive rats determined by a direct recording technique. Archives internationales de pharmaco-dynamie et de thérapie 154: 351–363 (1965).Google Scholar
  95. Staquet, M.; Yabo, R.; Viktora, J, and Wolff F: An adrenergic mechanism for hyperglycemia induced by diazoxide. Metabolism 14: 1000–1009(1965).PubMedCrossRefGoogle Scholar
  96. Steinke, J. and Soeldner, J.S.: Metabolic effects of dia-zoxide in normal subjects, patients with diabetes mellitus, and patients with organic hypoglycemia. Annals of the New York Academy of Sciences 150: 330–336(1968).CrossRefGoogle Scholar
  97. Sutherland, E.W.: On the biological role of cyclic AMP. Journal of the American Medical Association 214: 1281–1288(1970).PubMedCrossRefGoogle Scholar
  98. Suzuki, T.: Studies on the renin-angiotensin-aldosterone system: Effect of the antihypertensive agent diazoxide on plasma renin activity and its clinical application especially in screening primary aldosteronism and its similar disorders. Japanese Circulation Journal. 34: 187–197(1970).PubMedCrossRefGoogle Scholar
  99. Symchowicz, S.; Winston, L.; Black, J.; Smith, M.; Calesnick, B., and Tabachnick, U.A.: Diazoxide blood levels in man. Journal of Pharmaceutical Sciences 56: 912–914(1967).PubMedCrossRefGoogle Scholar
  100. Tabachnick, I.I.A. and Gulbenkian, A.: Mechanism of diazoxide hyperglycemia in animals. Annals of the New York Academy of Sciences 150: 204–218 (1968).PubMedCrossRefGoogle Scholar
  101. Tabachnick, U.A.; Gulbenkian, A., and Seidman, F.: The effect of a benzothiadiazine, diazoxide on carbohydrate metabolism. Diabetes 13: 408–418 (1964).PubMedGoogle Scholar
  102. Tabachnick, U.A.; Gulbenkian, A., and Seidman, F.: Further studies on the metabolic effects of diazoxide. Journal of Pharmacology and Experimental Therapeutics 150: 455–462 (1965).PubMedGoogle Scholar
  103. Taylor, R.M.: Renal aspects of certain antihypertensive agents. Angiology 14: 79–83 (1963).PubMedCrossRefGoogle Scholar
  104. Taylor, R.M. and Rubin, A.A.: Studies on the renal pharmacology of diazoxide, an antidiuretic benzothiadiazine. Journal of Pharmacology and Experimental Therapeutics; 144: 284–292(1964).PubMedGoogle Scholar
  105. Thompson, G.R.: The effect of diazoxide, potassium chloride, and ammonium chloride on serum and urinary uric acid. Arthritis and Rheumatism 8: 830–835(1965).PubMedCrossRefGoogle Scholar
  106. Thompson, G.R.; Anderson, R.W., and Ballantyne, L.M.: The effects of intravenous diazoxide, a non-diuretic thiazide, upon blood pressure, electrolyte, and uric acid excretion. Michigan Medicine 65: 17–21 (1966).Google Scholar
  107. Thomson, A.E.; Nickerson, M.; Gaskell, P., and Grahame, G.R.: Clinical observations on an antihypertensive chlorothiazide analogue devoid of diuretic activity. Canadian Medical Association Journal 87: 1306–1310(1962).PubMedGoogle Scholar
  108. Turtle, J.R.; Littleton, G.K., and Kipnis, D.M.: Stimulation of insulin secretion by theophylline. Nature 213: 727–728(1967).PubMedCrossRefGoogle Scholar
  109. Updike, S.J. and Harrington, A.R.: Acute diabetic keto-acidosis — A complication of intravenous diazoxide treatment for refractory hypertension. New England Journal of Medicine 280: 768 (1969).PubMedCrossRefGoogle Scholar
  110. Wade, D.N.: Personal communication (1971).Google Scholar
  111. Wales, J.K.; Grant, Alison M., and Wolff, F. W.: Reversal of diazoxide effects by tolbutamide. Lancet 1: 1137–1138 (1967).PubMedCrossRefGoogle Scholar
  112. Wales, J.K. and Wolff, F: Haematological side-effects of diazoxide. Lancet 1: 53–54(1967).PubMedCrossRefGoogle Scholar
  113. Walfish, P.G.; Renato, Natale, and Chang, Catherine: Beta adrenergic receptor mechanisms in the metabolic effects of diazoxide in fasted rats. Diabetes 19: 228–232(1970).PubMedGoogle Scholar
  114. Wilkenfeld, B.E. and Levy, B.: The effects of theophylline, diazoxide and imidazole on isoproterenol-induced inhibition of the rabbit ileum. Journal of Pharmacology and Experimental Therapeutics 169: 61–67 (1969).PubMedGoogle Scholar
  115. Wilson, W.R. and Okun, R.: The acute hemodynamic effects of diazoxide in man. Circulation 28: 89–93 (1963).PubMedCrossRefGoogle Scholar
  116. Wilson, W.R. and Kirkendall, W.M.: Effects on intravenous diazoxide in treatment of severe hypertension. Clinical Research 12: 196(1964).Google Scholar
  117. Wilson, W.R.; Stone, D.B.; Okun, R., and Russell, R.P.: Metabolic effects of diuretic and non-diuretic benzothiadiazines. Annals of Internal Medicine 60: 317 (1964).Google Scholar
  118. Winer, N.; Chokshi, D.S.; Yoon, M.S., and Freedman, A.D.: Adrenergic receptor mediation of renin secretion. Journal of Clinical Endocrinology 29: 1168–1175 (1969).CrossRefGoogle Scholar
  119. Wohl, A.J.; Hausler, Lorraine M., and Roth, F.E.: Studies on the mechanism of antihypertensive action of diazoxide: In vitro vascular pharmacodynamics. Journal of Pharmacology and Experimental Therapeutics 158: 531–539(1967).PubMedGoogle Scholar
  120. Wohl, A.J.; Hausler, Lorraine M., and Roth, F.E.: The role of calcium in the mechanism of the antihypertensive action of diazoxide. Life Sciences 7: 381–387 (1968a).PubMedCrossRefGoogle Scholar
  121. Wohl, A,J.; Hausier, Lorraine M., and Roth, F.E.: Mechanism of the antihypertensive effect of diazoxide: In vitro vascular studies in the hypertensive rat. Journal of Pharmacology and Experimental Therapeutics 162: 109–114 (1968b).PubMedGoogle Scholar
  122. Wolff, F.: Diazoxide hyperglycaemia and its continued relief by tolbutamide. Lancet 7: 309–310 (1964).CrossRefGoogle Scholar
  123. Wolff, F. and Parmley, W.W.: Aetiological factors in benzothiadiazine hyperglycaemia. Lancet 2: 69 (1963).PubMedCrossRefGoogle Scholar
  124. Zarday, Z.; Viktora, J., and Wolff, F: The effect of diazoxide on catecholamines. Metabolism 75: 257–261 (1966).CrossRefGoogle Scholar
  125. Zitowitz, L. and Rubin, A.A.: Some acute cardiovascular actions of diazoxide (SRG 95213), a non-diuretic antihypertensive benzothiadiazine. Federation Proceedings 21: 114(1962).Google Scholar

Copyright information

© Adis International Limited 1971

Personalised recommendations